BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 25709051)

  • 1. Current and Emerging Immunotherapies for Castration-resistant Prostate Cancer.
    Saad F; Miller K
    Urology; 2015 May; 85(5):976-986. PubMed ID: 25709051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer?
    Cha E; Small EJ
    Cancer Med; 2013 Apr; 2(2):243-52. PubMed ID: 23634292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospects for the use of ipilimumab in treating advanced prostate cancer.
    Wei XX; Fong L; Small EJ
    Expert Opin Biol Ther; 2016; 16(3):421-32. PubMed ID: 26698365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of immunotherapy in castration-resistant prostate cancer (CRPC).
    Suárez C; Morales-Barrera R; Ramos V; Núñez I; Valverde C; Planas J; Morote J; Maldonado X; Carles J
    BJU Int; 2014 Mar; 113(3):367-75. PubMed ID: 23650874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms.
    Quinn DI; Shore ND; Egawa S; Gerritsen WR; Fizazi K
    Urol Oncol; 2015 May; 33(5):245-60. PubMed ID: 25575714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy in prostate cancer: challenges and opportunities.
    Noguchi M; Koga N; Moriya F; Itoh K
    Immunotherapy; 2016; 8(1):69-77. PubMed ID: 26642100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.
    Gomella LG; Gelpi-Hammerschmidt F; Kundavram C
    Can J Urol; 2014 Apr; 21(2 Supp 1):48-56. PubMed ID: 24775724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New therapies in metastatic castration resistant prostate cancer].
    Thibault C; Massard C
    Bull Cancer; 2015 Jun; 102(6):501-8. PubMed ID: 26022286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer: current progress and clinical applications.
    Gulley JL; Madan RA; Heery CR
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular insights into the development of T cell-based immunotherapy for prostate cancer.
    Dong B; Minze LJ; Xue W; Chen W
    Expert Rev Clin Immunol; 2014 Nov; 10(11):1547-57. PubMed ID: 25259804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current role of immunotherapy for the treatment of prostate cancer.
    Porfyris O; Kalomoiris P
    J BUON; 2013; 18(4):809-17. PubMed ID: 24344002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications.
    Singh BH; Gulley JL
    Asian J Androl; 2014; 16(3):364-71. PubMed ID: 24435055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current status and prospects of immunotherapy for castration-resistant prostate cancer].
    Yatsuda J; Eto M
    Nihon Rinsho; 2014 Dec; 72(12):2174-8. PubMed ID: 25518354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Castration-resistant prostate cancer: from new pathophysiology to new treatment.
    Sridhar SS; Freedland SJ; Gleave ME; Higano C; Mulders P; Parker C; Sartor O; Saad F
    Eur Urol; 2014 Feb; 65(2):289-99. PubMed ID: 23957948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The treatment of castration-resistant prostate cancer].
    Petrányi Á
    Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New progress of castration-resistant prostate cancer immunotherapy].
    Liu JP; Wang H
    Zhonghua Wai Ke Za Zhi; 2016 Oct; 54(10):787-791. PubMed ID: 27686644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients.
    Cabel L; Loir E; Gravis G; Lavaud P; Massard C; Albiges L; Baciarello G; Loriot Y; Fizazi K
    J Immunother Cancer; 2017; 5():31. PubMed ID: 28428880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New and emerging agents for the treatment of castration-resistant prostate cancer.
    Higano CS; Crawford ED
    Urol Oncol; 2011; 29(6 Suppl):S1-8. PubMed ID: 22074657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging treatment options for patients with castration-resistant prostate cancer.
    George D; Moul JW
    Prostate; 2012 Feb; 72(3):338-49. PubMed ID: 21748753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic vaccines is a novel approach in castration-resistant prostate cancer treatment].
    Djurhuus SS; Brasso K; Berg KD; Iversen P; Røder MA
    Ugeskr Laeger; 2015 May; 177(20):. PubMed ID: 25967247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.